A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

被引：0
|
作者：
Yiyun Wang
Yingying Yang
Ruimin Hong
Houli Zhao
Guoqing Wei
Wenjun Wu
Huijun Xu
Jiazhen Cui
Yanlei Zhang
Alex H. Chang
Yongxian Hu
He Huang
机构：
[1] Zhejiang University School of Medicine,Bone Marrow Transplantation Center, The First Affiliated Hospital
[2] Zhejiang University,Institute of Hematology
[3] Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Zhejiang Laboratory for Systems & Precision Medicine
[4] Zhejiang University Medical Center,undefined
[5] Shanghai YaKe Biotechnology Ltd,undefined
来源：
Blood Cancer Journal | / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia
    Wang, Yiyun
    Yang, Yingying
    Hong, Ruimin
    Zhao, Houli
    Wei, Guoqing
    Wu, Wenjun
    Xu, Huijun
    Cui, Jiazhen
    Zhang, Yanlei
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [2] Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia
    Yang, Tingting
    Dong, Yetian
    Zhang, Mingming
    Feng, Jingjing
    Fu, Shan
    Xiao, Pingnan
    Hong, Ruimin
    Xu, Huijun
    Cui, Jiazhen
    Huang, Simao
    Wei, Guoqing
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    BLOOD, 2024, 144 : 2819 - 2819
  • [3] A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
    Hu, Yongxian
    Wang, Jiasheng
    Wei, Guoqing
    Yu, Jian
    Luo, Yi
    Shi, Jimin
    Wu, Wenjun
    Zhao, Kui
    Xiao, Lei
    Zhang, Yanlei
    Wu, Zhao
    Xu, Huijun
    Chang, Alex Hongsheng
    Huang, He
    BONE MARROW TRANSPLANTATION, 2019, 54 (08) : 1208 - 1217
  • [4] A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia
    Yongxian Hu
    Jiasheng Wang
    Guoqing Wei
    Jian Yu
    Yi Luo
    Jimin Shi
    Wenjun Wu
    Kui Zhao
    Lei Xiao
    Yanlei Zhang
    Zhao Wu
    Huijun Xu
    Alex Hongsheng Chang
    He Huang
    Bone Marrow Transplantation, 2019, 54 : 1208 - 1217
  • [5] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults
    Tu, Sanfang
    Zhou, Lijuan
    Huang, Rui
    Zhou, Xuan
    Yang, Jilong
    Li, Meifang
    Jin, Bo
    Wang, Langqi
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Li, Yuhua
    BLOOD, 2023, 142
  • [6] Preclinical Development of Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22
    Qin, Haiying
    Haso, Waleed
    Sang Minh Nguyen
    Fry, Terry J.
    BLOOD, 2015, 126 (23)
  • [7] 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL)
    Schultz, Liora M.
    Davis, Kara L.
    Baggott, Christina
    Chaudry, Christie
    Marcy, Anne Cunniffe
    Mavroukakis, Sharon
    Sahaf, Bita
    Kong, Katherine A.
    Muffly, Lori S.
    Kim, Stephen
    Meyer, Everett H.
    Fry, Terry J.
    Qin, Haiying
    Miklos, David B.
    Mackall, Crystal L.
    BLOOD, 2018, 132
  • [8] Correction to: Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
    Hanren Dai
    Zhiqiang Wu
    Hejin Jia
    Chuan Tong
    Yelei Guo
    Dongdong Ti
    Xiao Han
    Yang Liu
    Wenying Zhang
    Chunmeng Wang
    Yajing Zhang
    Meixia Chen
    Qingming Yang
    Yao Wang
    Weidong Han
    Journal of Hematology & Oncology, 13
  • [9] CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations
    Aiyun Jin
    Jingjing Feng
    Guoqing Wei
    Wenjun Wu
    Luxin Yang
    Huijun Xu
    Yanlei Zhang
    Jiazhen Cui
    Alex Hongsheng Chang
    Yongxian Hu
    He Huang
    Bone Marrow Transplantation, 2020, 55 : 717 - 721
  • [10] Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia
    Shi, Ming
    Li, Li
    Wang, Shiyuan
    Cheng, Hai
    Chen, Wei
    Sang, Wei
    Qi, Kunming
    Li, Zhenyu
    Wang, Gang
    Li, Huizhong
    Lan, Jianping
    Huang, Jinqi
    Fei, Xiaoming
    Yu, Min
    Li, Fei
    Qiao, Jianlin
    Wu, Qingyun
    Zeng, Lingyu
    Jing, Guangjun
    Zheng, Junnian
    Gale, Robert Peter
    Xu, Kailin
    Cao, Jiang
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (06) : 711 - 718
12345